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Abstract
Background: Neurofilament light chain (NF-L) levels reflect axonal damage in different conditions,
including demyelinating disorders.
Objectives: We aimed to compare serum NF-L levels in patients with aquaporin-4 antibodies (AQP4-
Ab), myelin oligodendrocyte antibodies (MOG-Ab) and seronegative cases with neuromyelitis optica
spectrum disorders and related disorders.
Methods: We analysed AQP4-Ab and MOG-Ab with cell-based assay and NF-L with ultrasensitive
electrochemiluminescence immunoassay.
Results: Median NF-L levels were increased in 25 AQP4-Ab-positive patients (59 pg/ml) as compared
with 22 MOG-Ab-positive cases (25 pg/ml), 52 seronegative patients (18 pg/ml), 25 multiple sclerosis
patients (12 pg/ml) and 14 healthy controls (12 pg/ml).
Conclusions: Increased serum levels of NF-L in patients with AQP4-Ab or MOG-Ab might reflect an
ongoing axonal damage and a more malignant disease course.
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Introduction
Cerebrospinal fluid (CSF) neurofilament light chain
(NF-L) has been proposed as potential biomarker of
disease activity in different conditions, including
multiple sclerosis (MS) and clinically isolated syn-
drome (CIS).1 The strong correlation between CSF
and serum NF-L, detected with ultrasensitive single-
molecule array, supports their value in monitoring
tissue damage and treatment response.2 Although
considered a useful biomarker in demyelinating dis-
orders, serum NF-L concentration has never been
investigated in neuromyelitis optica spectrum disor-
ders (NMOSD) according to antibody status. Our
objective was to analyse serum NF-L in patients
with NMOSD and related disorders and to compare
its level in cases with autoantibodies to aquaporin-4
(AQP4-Ab), myelin oligodendrocyte antibodies
(MOG-Ab) and seronegative patients.
Materials and methods
We identified patients referred for serum AQP4/
MOG-Ab analysis to the Laboratory of
Neuropathology, University of Verona, between
May 2014 and May 2017. Of the 454 consecutive
serum samples that were analysed, nine were found
to be AQP4-Ab positive and MOG-Ab negative, and
22 MOG-Ab positive and AQP4-Ab negative. To
extend the analysis, we retrospectively identified
16 AQP4-Ab positive cases among patients referred
for AQP4-Ab analysis between April 2012 and April
2014. Among seronegative cases, we excluded those
with a final diagnosis of non-inflammatory neuro-
logical disorders, other defined inflammatory
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disorders, CIS or MS. All samples obtained from
AQP4-Ab-positive and seronegative patients were
collected at disease onset, in the absence of any
disease-modifying treatment. Among MOG-Ab pos-
itive cases, 12 samples were obtained at onset, seven
during relapses, one in the course of progression and
two in the chronic stage (median time from disease
onset 0 months, range 0–264 months). Only one
MOG-Ab positive patient was under disease-
modifying treatment (mycophenolate mofetil) at
the time of sample collection. As controls we includ-
ed 25 MS patients and 14 healthy subjects. Five
cases with MS were under relapse at the time of
NF-L analysis, and 14 patients, all with a relapsing
course, had been undertaking treatment for at least
6 months. Median time from disease onset was 193
months (range 1–445) in patients with relapsing–
remitting MS (RRMS), and 219 months (range 75–
274) in those with progressive MS.
A commercial cell-based assay (Euroimmun,
Lu¨beck-Germany) was used for the detection of
AQP4-Ab. Seronegative cases with a history sugges-
tive for NMOSD were tested for AQP4-Ab using a
live cell-based assay at the Neurological Research
Laboratory of Innsbruck. The presence of MOG-
Ab was analysed by three independent investigators
(SF, SM, AF) at the Verona Neuropathology
Laboratory using recombinant live cell-based immu-
nofluorescence assay with HEK293A cells trans-
fected with full-length MOG (human MOG alpha-1
EGFP fusion protein) and incubated with CyTm
3-conjugated goat anti-human IgG antibody (HþL,
Jackson ImmunoResearch Laboratory, West Grove,
PA, USA; diluted 1:200 in PBS/10%FCS), as pre-
viously described.3,4 Data were collected as part of
standard clinical practice, and patients consented to
diagnostic procedures and sample storage at Verona
Neuropathology Laboratory. According to available
medical records, analysed patients were classified
into five diagnostic categories: NMOSD;5 idiopathic
optic neuritis (ON); idiopathic acute myelitis (AM);
ON and AM; other demyelinating disorders.
Idiopathic ON and/or AM were defined as acute/sub-
acute optic neuropathy and/or myelopathy of inflam-
matory origin not fulfilling other established
diagnostic criteria. Other demyelinating disorders
were characterized by inflammatory conditions
with clinical, CSF and radiological evidence, not
included in the disorders previously mentioned.
Serum NF-L levels were quantified by an investiga-
tor blinded to patient data (AF), using a highly
sensitive electrochemiluminescence based
immunoassay as previously reported.6 Briefly, dilut-
ed sera and standards were incubated in duplicate in
Meso Scale Discovery (MSD) plates previously
coated (mAB 47:3, UmanDiagnostics). After block-
ing and washing, biotinylated secondary antibody
(mAB 2:1, UmanDiagnostics) was added. SULFO-
TAGTM-labelled streptavidin and ECL read buffer
(MSD) were added and signal was measured with
QuickPlex SQ120. Data were analysed by
Discovery Workbench 4.0 software, MSD, using a
four-parameter weighted logistic curve. The lower
detectable value was 12 pg/ml, according to the stan-
dard curve.
Statistical analysis was performed using IBM SPSS,
release V.24.0. We compared clinical, demographic
and serological data using the Kruskal–Wallis test
with Dunn’s multiple comparison test, Chi-square
test and binary logistic regression analysis (enter
model). Statistical significance was defined as a
two-sided p-value of <0.05 and p-values were cor-
rected for multiple comparison using Bonferroni’s
correction if applicable. Sex and age were used as
covariates, in accordance to previous reports.2
Results
All patients with AQP4-Ab had a final diagnosis of
NMOSD. The most frequently observed final diag-
nosis among MOG-Ab-positive patients was ON
(10), followed by other demyelinating disorders
(6), ONþAM (3), AM (2) and MS (1). A monopha-
sic course was observed in 45.5% of patients, a
relapsing one in 50% and a gradually evolving
course in 4.5%. Seronegative cases had a final diag-
nosis of ON (22), AM (23) and NMOSD (7). Among
patients with MS the course was relapsing–remitting
in 18, primary progressive in three (PPMS), and sec-
ondary progressive in four (SPMS) cases. The
median Expanded Disability Status Scale score at
the time of sampling was 2.75 (range 1–6) in patients
with RRMS and 6.5 (range 6–8.5) in cases with pro-
gressive MS.
Median serum NF-L concentration was significantly
higher in patients with AQP4-Ab (59 pg/ml) com-
pared with healthy controls (12 pg/ml), and was also
increased in MOG-Ab positive (25 pg/ml) and sero-
negative patients (18 pg/ml), although the latter did
not reach significant difference (Table 1). Detectable
levels of NF-L (15 pg/ml, 12 pg/mlþ 20% to cor-
rect for measurement error) were more frequently
observed in patients with AQP4-Ab (68%) and
MOG-Ab (70%) as compared with seronegative
cases (57%), patients with MS (44%) or healthy
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controls (29%). Overall, NF-L levels were signifi-
cantly increased in AQP4-Ab and MOG-Ab positive
patients as compared with healthy controls (Table 1).
Discussion
In patients with demyelinating disorders, increasing
attention has recently been paid to biomarkers which
reflect neural tissue damage and predict long-term
disability. In particular, glial fibrillary acid protein
(GFAP) had been indicated as a biomarker of astro-
cytic damage and clinical severity in patients with
NMOSD.7 Moreover, it was shown that myelin basic
protein is elevated in the CSF of both AQP4-Ab and
MOG-Ab-positive patients as compared with MS
patients, while GFAP is higher only in AQP4-Ab-
positive ones, reflecting either myelin injury or
astrocyte damage, respectively.8 In this scenario,
the role of axonal damage reflected by elevation of
neuron-specific biomarkers located in axons is
unclear. An increase of NF-heavy and light chains
has been demonstrated in CSF of patients with
NMOSD compared with MS cases, suggesting the
implication of axonal injury.9 However, previous
reports were mainly focused on CSF analysis, and
did not account for the presence of specific antibod-
ies which might induce prominent damage at their
target site. We here report the first observation of
increased serum NF-L levels in patients with AQP4-
Ab and MOG-Ab, compared with seronegative ones.
Our study is limited by the relatively small number
of patients and by the partial availability of clinical
data that did not allow an extensive comparison of
clinical, radiological and laboratory findings in the
whole cohort. Compared with previous studies, we
observed lower NF-L levels in patients with MS,
probably related to the absence of recent relapses
in most of them, and to the fact that most of these
patients were under treatment.2 In contrast, NF-L
levels observed in healthy controls were compara-
ble.2,6 The high NF-L levels associated with AQP4-
Ab might in part explain the more severe clinical
phenotype observed in these patients, reflecting the
axonal injury induced by astrocytic and
complement-mediated cellular damage. On the
other hand, in MOG-Ab positive patients, the rela-
tively increased levels of the axonal biomarker NF-L
could reflect the long-term disability described in
many MOG-Ab-positive cases, suggesting that
myelin and neuronal damage may coexist in this
condition.
Conclusion
Our data demonstrate that serum NF-L concentration
is elevated in patients with MOG-Ab and, promi-
nently, with AQP4-Ab-associated NMOSD and
related disorders, possibly reflecting axonal injury.
Future studies correlating NF-L levels, disease
course and therapeutic effectiveness are required in
order to establish the role of NF-L as a biomarker of
disease activity in these conditions.
Table 1. Serum neurofilament light chain levels in patients with NMOSD and related disorders, MS and
healthy controls according to antibody reactivity to AQP4 and MOG.
NMOSD and related disorders Controls
AQP4-Ab
positive
MOG-Ab
positive Seronegative MS HC p-value
Number 25 22 52 25 14
Females 23 (92%) 12 (54%) 34 (65%) 16 (64%) 9 (64%) 0.064a
Age 51 (31–79) 40 (15–64) 44 (21–69) 44 (28–67) 37 (26–62) 0.095b
Serum NF-L (pg/ml) 59 (12–994)* 25 (12–140) 18 (12–540) 12 (12–1464) 12 (12–788) 0.021b
Serum NF-L 15 pg/ml
(detectable levels)
17 (68%)
p¼ 0.034c
14 (70%)
p¼ 0.019c
31 (57%)
p¼ 0.077c
11 (44%)
p¼ 0.417c
4 (29%)
reference
0.018c
Groups were statistically compared with aChi-square test, bKruskal–Wallis test (data shown as median with 9 th–95 th
percentile range) and cbinary logistic regression analysis (enter model) with age and sex as covariates. * Statistically
significant difference to HC (corrected p-value <0.05).
Ab: antibody; AQP4: Aquaporin-4; HC: healthy controls; MOG: myelin oligodendrocyte glycoprotein; MS: multiple
sclerosis; NF-L: neurofilament light chain; NMOSD: Neuromyelitis optica spectrum disorders.
AQP4-ab positive: NMOSD (25); MOG-Ab positive: ON (10), AM (2), ONþAM (3), other demyelinating disorders
(6), MS (1); seronegative: ON (22), AM (23), NMOSD (7); MS: RRMS (18), SPMS (4), PPMS (3).
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